Briefing: The 'croak' conundrum: Parasites complicate love signals in frogs
Strategic angle: Parasites interfere with the acoustic signals frogs use to attract mates, complicating their reproductive success.
Briefing: Why BTIG Downgraded OneStream (OS) After Its $24-Per-Share Buyout Agreement
Strategic angle: An analysis of BTIG's decision to downgrade OneStream following its buyout announcement.
Briefing: Why D.A. Davidson Stayed Neutral on Clearwater Analytics (CWAN) Amid Its Pending Take-Private Deal
Strategic angle: D.A. Davidson's stance on Clearwater Analytics reflects cautious optimism amidst market fluctuations.
Briefing: Why EverCommerce’s (EVCM) Latest Update Was an Insider Sale, Not an Operating Shift
Strategic angle: An analysis of EverCommerce's recent update reveals it was driven by insider sales rather than operational changes.
Briefing: Musicality is rooted in human biology, not just culture, says professor
Strategic angle: New research suggests that our capacity for music is fundamentally biological.
Briefing: How biological invasions are silently remodeling ecosystems
Strategic angle: Many of the most damaging invasions do not simply subtract species; they fundamentally remodel the environment, altering habitats, rewiring interactions, and shifting processes in ways that species lists alone cannot reveal.
Briefing: Trump-backed SAVE America Act will get a Senate vote next week, Thune says
Strategic angle: Advocates of the voter-ID bill have pressed the Senate for months to call a vote on the controversial legislation.
Briefing: Honda Is Done With EVs In The U.S.
Strategic angle: We're looking at the end of Honda EVs in the States, as well as U.S. buyers' love affair with cheap used EVs and more.
Briefing: Once-overpriced iPhone Air and Galaxy S25 cases are now 90 percent off
Strategic angle: Affordable phone cases are now available at a fraction of the original price.
Briefing: FDA launches unified system for adverse event reports
Strategic angle: BIO's Crowley warns U.S. risks losing lead, a familiar red flag with Aldeyra, and other biotech news from The Readout.
Briefing: Astronomers discuss fortifying our planetary defenses
Strategic angle: Experts emphasize the need to prepare for smaller asteroids that could impact modern society.
Briefing: The rain in Spain was worst in nearly 50 years
Strategic angle: Spain endured its wettest January and February in almost half a century, with a string of deadly storms lashing the country.
Briefing: Israel pounds Lebanon: Grieving border village calls for peace
Strategic angle: In the south Lebanon border village of Qlayaa, hundreds mourn parish priest Father Pierre al-Rai two days after he was killed by Israeli shelling while inspecting the site of an earlier attack.
Briefing: Iran new supreme leader Khamenei's wealth estimated at more than $100 billion
Strategic angle: An investigation reveals the immense wealth of Mojtaba Khamenei, the newly appointed head of the Islamic Republic.
Briefing: Hamilton to miss Oscars despite 'F1' nominations
Strategic angle: Lewis Hamilton has explored "every way" to attend Sunday's Oscars ceremony following the Chinese Grand Prix, but ultimately decided it was impossible to arrive on time.
Briefing: Driver Claims Autopilot Tried To Send Her Cybertruck Straight Off A Houston Bridge
Strategic angle: Tesla faces a Texas lawsuit after a Cybertruck crash that allegedly occurred while the vehicle was using Full-Self Driving (Supervised).
Briefing: Dave Ramsey tells homeless, unemployed Ohio man with $14K debt there’s no point declaring bankruptcy. Here’s why
Strategic angle: Financial advice from Dave Ramsey on managing debt without bankruptcy.
Briefing: Papa John’s weighs Irth Capital’s $1.5bn take-private bid – report
Strategic angle: Papa John’s is considering a $1.5 billion bid from Irth Capital to take the company private.
Briefing: China passes controversial 'ethnic unity' law
Strategic angle: The new law mandates Mandarin as the official language, raising concerns over minority rights.
Briefing: STAT+: Is Aldeyra Therapeutics waving red flags with consequences?
Strategic angle: How often do drugmakers complain about short sellers in SEC filings? And does it do any good?